[go: up one dir, main page]

NO971568L - Keratinocyte growth factor analogues - Google Patents

Keratinocyte growth factor analogues

Info

Publication number
NO971568L
NO971568L NO971568A NO971568A NO971568L NO 971568 L NO971568 L NO 971568L NO 971568 A NO971568 A NO 971568A NO 971568 A NO971568 A NO 971568A NO 971568 L NO971568 L NO 971568L
Authority
NO
Norway
Prior art keywords
growth factor
keratinocyte growth
factor analogues
analogues
keratinocyte
Prior art date
Application number
NO971568A
Other languages
Norwegian (no)
Other versions
NO318761B1 (en
NO971568D0 (en
Inventor
Charles F Morris
William C Kenney
Bao-Lu Chen
Eric W Hsu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO971568D0 publication Critical patent/NO971568D0/en
Publication of NO971568L publication Critical patent/NO971568L/en
Publication of NO318761B1 publication Critical patent/NO318761B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method and pharmaceutical compositions are described for the use of keratinocyte growth factor to treat diabetes in mammals.
NO19971568A 1994-10-13 1997-04-04 Polypeptide Analog to Native Keratinocyte Growth Factor Called "KGF", Pharmaceutical Formulation, Recombinant Nucleic Acid Molecule, Biological Functional Vector, Prokaryotic or Eukaryotic Host Cell, Process for Preparation of an Analog of KGF, Use of an Effective Amount of Invention of the KGF of a drug for stimulating the production of non-fibroblast epithelial cells, in vitro methods for stimulating the production of non-fibroblast epithelial cells, and kits. NO318761B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000971 WO1996011949A2 (en) 1994-10-13 1995-10-12 Analogs of keratinocyte growth factor

Publications (3)

Publication Number Publication Date
NO971568D0 NO971568D0 (en) 1997-04-04
NO971568L true NO971568L (en) 1997-06-12
NO318761B1 NO318761B1 (en) 2005-05-02

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19971568A NO318761B1 (en) 1994-10-13 1997-04-04 Polypeptide Analog to Native Keratinocyte Growth Factor Called "KGF", Pharmaceutical Formulation, Recombinant Nucleic Acid Molecule, Biological Functional Vector, Prokaryotic or Eukaryotic Host Cell, Process for Preparation of an Analog of KGF, Use of an Effective Amount of Invention of the KGF of a drug for stimulating the production of non-fibroblast epithelial cells, in vitro methods for stimulating the production of non-fibroblast epithelial cells, and kits.
NO971566A NO971566L (en) 1994-10-13 1997-04-04 Method of treating diabetes mellitus using KGF

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO971566A NO971566L (en) 1994-10-13 1997-04-04 Method of treating diabetes mellitus using KGF

Country Status (23)

Country Link
EP (2) EP0785948B1 (en)
JP (2) JP4216329B2 (en)
KR (1) KR100278597B1 (en)
CN (1) CN1168678A (en)
AT (2) ATE237633T1 (en)
AU (1) AU3707795A (en)
BG (2) BG101392A (en)
BR (2) BR9509329A (en)
CA (2) CA2202075C (en)
CZ (3) CZ98197A3 (en)
DE (2) DE69535264T2 (en)
DK (2) DK0785948T3 (en)
EE (2) EE03975B1 (en)
ES (2) ES2196082T3 (en)
FI (2) FI971420A0 (en)
HU (2) HUT78050A (en)
NO (2) NO318761B1 (en)
NZ (2) NZ505502A (en)
PL (2) PL182888B1 (en)
PT (2) PT804479E (en)
SI (2) SI0804479T1 (en)
SK (2) SK284534B6 (en)
WO (2) WO1996011949A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (en) 1989-01-31 2001-03-16 Jeffrey S Rubin DNA CODING A SPECIFIC GROWTH FACTOR AGAINST EPITHELIAL CELLS.
BR9407035A (en) 1993-06-29 1996-03-12 Chiron Corp Fragment of keratinocyte growth factor conjugated therapeutic composition DNA molecule expression vector host cell process to produce fragment of keratinocyte growth factor process for wound healing and process of treatment of hyperproliferative disease of the epidermis
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2197926T3 (en) * 1994-10-13 2004-01-16 Amgen Inc. METHOD TO PURIFY FACTORS OF GROWTH OF KERATINOCITS.
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
DK0822943T3 (en) * 1995-04-27 1999-11-29 Cooperatie Cosun U A inulin
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
ES2218666T3 (en) * 1996-10-15 2004-11-16 Amgen Inc., PRODUCT BASED ON THE GROWTH FACTOR OF QUERATINOCITOS-2 (KGGF-2).
EP1473366A1 (en) * 1996-10-15 2004-11-03 Amgen Inc. Keratinocyte growth factor-2 products
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
KR20010033484A (en) 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
KR100731826B1 (en) * 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 Method for preparing a protein containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
KR20030074791A (en) * 2001-02-06 2003-09-19 메르크 파텐트 게엠베하 Modified keratinocyte growth factor (kgf) with reduced immunogenicity
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
MXPA04001526A (en) 2001-08-21 2004-05-31 Chiron Corp Kgf polypeptide compositions.
PL1827483T3 (en) 2004-12-15 2014-12-31 Swedish Orphan Biovitrum Ab Publ Therapeutic formulations of keratinocyte growth factor
CN102242124B (en) * 2010-05-10 2013-05-22 齐鲁制药有限公司 Modified Keratinocyte growth factor gene and its expression in yeast
KR102440312B1 (en) * 2020-08-28 2022-09-05 한국해양과학기술원 Thermally stable fgf7 polypeptide and use of the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (en) * 1987-08-10 1989-05-30 Shionogi & Co Ltd Reg protein
US5145225A (en) * 1988-07-27 1992-09-08 Muller George M Carpet stretcher
ES2153816T3 (en) * 1989-01-31 2001-03-16 Jeffrey S Rubin DNA CODING A SPECIFIC GROWTH FACTOR AGAINST EPITHELIAL CELLS.
JP3303211B2 (en) * 1991-04-26 2002-07-15 武田薬品工業株式会社 bFGF mutein and method for producing the same
UA46706C2 (en) * 1993-03-26 2002-06-17 Амген Інк. METHOD OF TREATMENT AND PREVENTION OF THE PATIENT'S DISEASE, PHARMACEUTICAL COMPOSITION
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
BR9407035A (en) * 1993-06-29 1996-03-12 Chiron Corp Fragment of keratinocyte growth factor conjugated therapeutic composition DNA molecule expression vector host cell process to produce fragment of keratinocyte growth factor process for wound healing and process of treatment of hyperproliferative disease of the epidermis
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
AU7475694A (en) * 1993-08-02 1995-02-28 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
SK45597A3 (en) 1999-02-11
EP0785948A1 (en) 1997-07-30
AU681546B2 (en) 1997-08-28
NZ505502A (en) 2005-01-28
SK43197A3 (en) 1999-03-12
FI120040B (en) 2009-06-15
PT804479E (en) 2007-02-28
EP0804479A1 (en) 1997-11-05
PL319784A1 (en) 1997-08-18
CZ297329B6 (en) 2006-11-15
DE69535264D1 (en) 2006-11-23
ES2273338T3 (en) 2007-05-01
CZ105097A3 (en) 1998-10-14
DE69530403T2 (en) 2003-10-30
AU3707795A (en) 1996-05-06
HU226168B1 (en) 2008-05-28
BG101408A (en) 1997-12-30
KR100278597B1 (en) 2001-01-15
CA2201940A1 (en) 1996-04-25
NO971566L (en) 1997-04-14
WO1996011949A2 (en) 1996-04-25
ATE237633T1 (en) 2003-05-15
FI971536L (en) 1997-06-09
DE69530403D1 (en) 2003-05-22
CA2202075C (en) 2003-12-09
FI971420A7 (en) 1997-04-04
FI971420L (en) 1997-04-04
EP0785948B1 (en) 2003-04-16
NO318761B1 (en) 2005-05-02
PL320484A1 (en) 1997-09-29
PL182888B1 (en) 2002-03-29
BR9509269A (en) 1997-12-23
PT785948E (en) 2003-09-30
CZ98197A3 (en) 1998-11-11
EE9700225A (en) 1998-02-16
FI971536A0 (en) 1997-04-11
NZ335109A (en) 2000-08-25
DE69535264T2 (en) 2007-02-01
FI971420A0 (en) 1997-04-04
BG101392A (en) 1997-10-31
CA2201940C (en) 2009-05-12
SI0785948T1 (en) 2003-08-31
CN1168678A (en) 1997-12-24
JPH10507193A (en) 1998-07-14
JPH10507080A (en) 1998-07-14
NO971568D0 (en) 1997-04-04
SI0804479T1 (en) 2006-12-31
DK0785948T3 (en) 2003-08-04
ES2196082T3 (en) 2003-12-16
AU3708395A (en) 1996-05-06
CA2202075A1 (en) 1996-04-25
EP0804479B1 (en) 2006-10-11
BG63167B1 (en) 2001-05-31
HUT78050A (en) 1999-07-28
WO1996011950A1 (en) 1996-04-25
JP4216329B2 (en) 2009-01-28
ATE342278T1 (en) 2006-11-15
SK284534B6 (en) 2005-06-02
HUT78058A (en) 1999-07-28
WO1996011949A3 (en) 1996-12-12
DK0804479T3 (en) 2007-01-29
EE9700081A (en) 1997-10-15
BR9509329A (en) 1997-10-14
NO971566D0 (en) 1997-04-04
EE03975B1 (en) 2003-02-17
JP4426646B2 (en) 2010-03-03
CZ297328B6 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
NO971568L (en) Keratinocyte growth factor analogues
FI973828A0 (en) Compounds and compositions for administering the active ingredients
FI970522L (en) Compositions and methods for providing prolonged local anesthesia
CA2160966A1 (en) Piperidine derivatives; process for preparing them and compositions containing the same
DE69027865D1 (en) COMPOSITIONS containing omega conotoxin peptide derivatives and their use for the treatment of ischemic-like neuronal damage
ES2186783T3 (en) DERIVATIVES OF DOLASTATINE, ITS PREPARATION AND USE.
ATE116848T1 (en) USE OF BACLOFEN IN THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF ANGINA PECTORIS.
FI895910A7 (en) Antiseptic compositions and method for their preparation
DK0460062T3 (en) Huperzin A analogues
ATE55695T1 (en) USE OF DEFIBROTIDE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ARTERIOPATHIES.
DE69405919D1 (en) Compositions for the treatment of keratin fibers
FI973040L (en) Racemization process for use in the preparation of levobupivacaine and closely related piperidinecarboxanilide anesthetics
DE69111768D1 (en) Enzymatic composition for the determination of ethanol.
DE59607481D1 (en) Powder mixture for the production of an opaque in paste form
ATE234614T1 (en) USE OF SELEGILINE TO TREAT HEARING LOSS IN MAMMALS
BG102771A (en) Diarylmethylidenfuran derivatives, method for their preparation and utilization as medicamentous forms
DE69734349D1 (en) TREATMENT OF BONE DRESS WITH ADRENOMEDULLIN
ATE204286T1 (en) MODIFIED ALPHA-D-GLCP-(1,2)-ALPHA-D-GLCP-(1, 3)-ALPHA-D-GLCP ANALOGUES
NO984198D0 (en) Method of treating aggression
ATE334672T1 (en) GINKOLIDE FOR INHIBITING MEMBRANE EXPRESSION
UA43389C2 (en) METHOD OF REDUCING SERUM CALCIUM LEVELS
DK0741746T3 (en) Thymosin alpha 1 analogues
GR1001368B (en) Pharmaceutical agents.
ECSP961819A (en) NEW FARNESIL-TRANSFERASA INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINED (CASE ST 95042)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees